Rationality of compound drug components against hypertension

doi:10.19803/j.1672-8629.20240278

Abstract

Abstract: Objective To analyze the marketed combination antihypertensive drugs and the rationality of their components, explore their composition and assess their efficacy so as to provide references for the development and innovation of combination antihypertensive drugs. Methods The marketed compound drug combinations and approved drug combination therapy regimens were analyzed and summarized by searching domestic and foreign literature. Results With multiple mechanisms of action, compound antihypertensive drugs could improve drug compliance, reduce cardiovascular risks, and lower overall treatment cost. Conclusion Compound antihypertensive drugs have unique advantages in the treatment of hypertension. Compound drugs are also the best choice for the treatment of hypertension and concomitant diseases, which will provide a new impetus for the development of compound drugs in the future.

Key words: hypertension, antihypertensive drugs, compound preparation, single-pill combinations, drug development, combination therapy

CLC Number:

R916
R972

GUO Shushu, JIANG Haiyan, FAN Xiaoyu, LI Wanfang, BAO Jie, MA Enlong, JIN Hongtao. Rationality of compound drug components against hypertension[J]. Chinese Journal of Pharmacovigilance, 2024, 21(9): 973-977.

Add to citation manager EndNote|Ris|BibTeX

URL: https://zgywjj.magtechjournal.com/EN/10.19803/j.1672-8629.20240278

https://zgywjj.magtechjournal.com/EN/Y2024/V21/I9/973

References

[1] NGUYEN TN, CHOW CK.Global and national high blood pressure burden and control[J]. Lancet, 2021, 398(10304): 932-933.
[2] HU SS, WANG ZW.Overview of report on cardiovascular health and diseases in China 2022[J]. Chinese Journal of Cardiovascular Research(中国心血管病研究), 2023, 21(7): 577-600.
[3] AL GHORANI H, GÖTZINGER F, BÖHM M, et al. Arterial hypertension-clinical trials update 2021[J]. Nutr Metab Cardiovasc Dis, 2022, 32(1): 21-31.
[4] AL-MAKKI A, DIPETTE D, WHELTON PK, et al.Hypertension pharmacological treatment in adults: A World Health Organization guideline executive summary[J]. Hypertension, 2022, 79(1): 293-301.
[5] MANCIA G, KREUTZ R, BRUNSTRÖM M, et al. 2023 ESH Guidelines for the Management of Arterial Hypertension the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension: Endorsed by the International Society of Hypertension(ISH) and the European Renal Association (ERA)[J]. J Hypertens, 2023, 41(12): 1874-2071.
[6] UNGER T, BORGHI C, CHARCHAR F, et al.2020 International Society of Hypertension Global Hypertension Practice Guidelines[J]. J Hypertens, 2020, 38(6): 982-1004.
[7] WILLIAMS B, MANCIA G, SPIERING W, et al.2018 ESC/ESH Guidelines for the Management of Arterial Hypertension[J]. Eur Heart J, 2018, 39(33): 3021-3104.
[8] XIE MX, LIANG HS.Single-pill combination in essential hypertension[J]. Advances in Cardiovascular Diseases(心血管病学进展) , 2022, 43(12): 1096-1100.
[9] CHEN GL, ZHANG L, CHEN P, et al.The status and prospect of research and development of drug combinations[J]. Chinese Journal of New Drugs(中国新药杂志), 2016, 25(19): 2205-2210.
[10] WANG W.New trends in hypertension treatment drugs: exploration of single tablet compound formulations[J]. Journal of China Prescription Drug(中国处方药), 2015, 13(4): 30-31.
[11] SARZANI R, LAURETI G, GEZZI A, et al.Single-pill fixed-dose drug combinations to reduce blood pressure: the right pill for the right patient[J]. Ther Adv Chronic Dis, 2022, 13: 20406223221102754.
[12] PACZKOWSKA-WALENDOWSKA M, SIP S, STASZEWSKI R, et al.Single-pill combination to improve hypertension treatment: pharmaceutical industry development[J]. Int J Environ Res Public Health, 2022, 19(7): 4156.
[13] UNGER T, BORGHI C, CHARCHAR F, et al.2020 International Society of Hypertension Global Hypertension Practice Guidelines[J]. Hypertension, 2020, 75(6): 1334-1357.
[14] SUÁREZ C. Single-pill telmisartan and amlodipine: a rational combination for the treatment of hypertension[J]. Drugs, 2011, 71(17): 2295-2305.
[15] SEGURA J, RUILOPE LM.A review of the benefits of early treatment initiation with single-pill combinations of telmisartan with amlodipine or hydrochlorothiazide[J]. Vasc Health Risk Manag, 2013, 9: 521-528.
[16] WHITE WB, LITTLEJOHN TW, MAJUL CR, et al.Effects of telmisartan and amlodipine in combination on ambulatory blood pressure in stages 1-2 hypertension[J]. Blood Press Monit, 2010, 15(4): 205-212.
[17] WANG JG, PALMER BF, ANDERSON VK, et al.Amlodipine in the current management of hypertension[J]. J Clin Hypertens(Greenwich), 2023, 25(9): 801-807.
[18] SUNG J, AHN KT, CHO BR, et al.Adherence to triple-component antihypertensive regimens is higher with single-pill than equivalent two-pill regimens: a randomized controlled trial[J]. Clin Transl Sci, 2021, 14(3): 1185-1192.
[19] CUI Z, QIU Z, CHENG W, et al.Efficacy and safety of olmesartan medoxomil-amlodipine besylate tablet in Chinese patients with essential hypertension: a prospective, single-arm, multi-center, real-world study[J]. J Clin Hypertens(Greenwich), 2024, 26(1): 5-16.
[20] SYED YY.Perindopril/Indapamide/Amlodipine in hypertension: a profile of its use[J]. Am J Cardiovasc Drugs, 2022, 22(2): 219-230.
[21] MCNALLY RJ, MORSELLI F, FARUKH B, et al.A review of the prescribing trend of thiazide-type and thiazide-like diuretics in hypertension: a UK perspective[J]. Br J Clin Pharmacol, 2019, 85(12): 2707-2713.
[22] BORGHI C, JAYAGOPAL PB, KONRADI A, et al.Adherence to triple single-pill combination of Perindopril/Indapamide/Amlodipine: findings from real-world analysis in Italy[J]. Adv Ther, 2023, 40(4): 1765-1772.
[23] LI ZX, ZHOU BL.New progress in the application research of sacubitril and valsartan in cardiovascular diseases[J]. Qinghai Medical Journal(青海医药杂志), 2023, 53(1): 61-64.
[24] PRZEZAK A, BIELKA W, PAWLIK A.Hypertension and type 2 diabetes-the novel treatment possibilities[J]. Int J Mol Sci, 2022, 23(12): 6500.
[25] DOCHERTY KF, VADUGANATHAN M, SOLOMON SD, et al.Sacubitril/Valsartan: Neprilysin inhibition 5 years after PARADIGM-HF[J]. JACC Heart Fail, 2020, 8(10): 800-810.
[26] GU J, NOE A, CHANDRA P, et al.Pharmacokinetics and pharmacodynamics of LCZ696, a novel dual-acting angiotensin receptor-neprilysin inhibitor (ARNi)[J]. J Clin Pharmacol, 2010, 50(4): 401-414.
[27] GE JB, HUO Y, BAO LW, et al.Chinese expert consensus on application of fixed-dose combination pill for the prevention and treatment of cardiovascular disease[J]. Chinese Circulation Journal(中国循环杂志), 2023, 38(9): 901-910.
[28] SEVER PS, DAHLÖF B, POULTER NR, et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian cardiac outcomes trial-lipid lowering arm (ASCOT-LLA): a multicentre randomised controlled trial[J]. Lancet, 2003, 361(9364): 1149-1158.
[29] YUSUF S, LONN E, PAIS P, et al.Blood-pressure and cholesterol lowering in persons without cardiovascular disease[J]. N Engl J Med, 2016, 374(21): 2032-2043.
[30] LIP GY, FELMEDEN DC, DWIVEDI G. Antiplatelet agents and anticoagulants for hypertension[J]. Cochrane Database Syst Rev, 2011, 2011(12): Cd003186.
[31] VEMULAPALLI S, HELLKAMP AS, JONES WS, et al.Blood pressure control and stroke or bleeding risk in anticoagulated patients with atrial fibrillation: results from the rocket AF trial[J]. American Heart Journal, 2016, 178: 74-84.
[32] MOSENZON O, ALGUWAIHES A, LEON JLA, et al.Capture: a multinational, cross-sectional study of cardiovascular disease prevalence in adults with type 2 diabetes across 13 countries[J]. Cardiovasc Diabetol, 2021, 20(1): 154.
[33] ABDELBAGI O, MUSA IR, MUSA SM, et al.Prevalence and associated factors of hypertension among adults with diabetes mellitus in northern Sudan: a cross-sectional study[J]. BMC Cardiovasc Disord, 2021, 21(1): 168.
[34] KHANGURA D, KURUKULASURIYA LR, WHALEY-CONNELL A, et al.Diabetes and hypertension: clinical update[J]. Am J Hypertens, 2018, 31(5): 515-521.
[35] MA KS.The clinical effect of trimetazidine in patients with unstable angina pectoris complicated with diabetes mellitus[J]. Diabetes New World(糖尿病新世界), 2021, 24(6): 105-108.